[Development of cancer immunotherapy by a combination of biological response modifiers on the basis of their mechanism of action].
The enhancement of antitumor effects by combination of biological response modifiers (BRM) was investigated on the basis of their action mechanisms. Experimentally, significant inhibition of tumor growth by combination treatment with BRM, which eliminated immune suppressive mechanisms and in turn enhanced immune responses, was observed. Furthermore, inhibition of tumor growth was observed under conditions of uniform biorhythm in mice and the effect of modification of biorhythm was enhanced by combination with BRM. Clinically, combination treatment of plasma exchange and LAK-cell adoptive immunotherapy was discussed.
D000818:Animals; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy / Q000379:methods*; D007370:Interferon Type I / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D008114:Liver Neoplasms, Experimental / Q000628:therapy; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000628:therapy*; D010507:Periodicity; D010844:Picibanil / Q000627:therapeutic use; D010951:Plasma Exchange; D011134:Polysaccharides / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000628:therapy; D014815:Vitamins / Q000627:therapeutic use
D007370:Interferon Type I; D007376:Interleukin-2; D011134:Polysaccharides; D014815:Vitamins; D010844:Picibanil; C010491:neurotropin